|
Mr. McWilliams, is an executive with over 30 years experience building public and private biopharmaceutical/healthcare companies. He is currently CEO of Opexa Therapeutics, Inc. (OPXA). Since 1992, Mr. McWilliams was President, CEO and Director of Encysive Pharmaceuticals (ENCY). At Encysive, he raised $250 million in public financings and corporate partnerships; licensed, developed and got FDA approval for anticoagulant (Argatroban - launched by GSK in 4Q2000); and built a portfolio of products through acquisition and internal discovery, with three compounds in Phase II/III testing for four indications. From 1980 to 1992, Mr. McWilliams was President and CEO of several healthcare companies. From 1972 to 1980, he was an executive at Abbott Laboratories, rising up to General Manager of South Africa. Previously, he was a management consultant at McKinsey & Co. Mr. McWilliams received an MBA in Finance from University of Chicago, and B.A. in Chemistry, Phi Beta Kappa, from Washington and Jefferson College. Mr. McWilliams has been a Director of Texas Health Plan, GenTrans Technology, Zonagen (ZONA), Encysive Pharmaceuticals (ENCY), DIFCO Laboratories and Structural Bioinformatics. He is currently a Director of Fairway Medical Technologies, Houston Technology Center, and Texas Healthcare and Bioscience Institute. | 